GlassScriptPhysician profile
Nora Bolanos
NPI 1578964177
$1,702.67
in general payments reported to CMS, 2019-2025
31 companies · $1,447 in 2025
The $1,447 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $255 · 2025: $1,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.69 |
| Education | $273.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $233.41 | 2025 | Rybrevant, Talvey, Darzalex |
| Merck Sharp & Dohme LLC | $189.05 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Stemline Therapeutics INC. | $141.59 | 2025 | Orserdu |
| Glaxosmithkline, LLC. | $109.48 | 2025 | Ojjaara |
| Gilead Sciences, INC. | $99.99 | 2025 | Trodelvy |
| Emd Serono, INC. | $80.25 | 2023 | |
| Seagen INC. | $74.99 | 2025 | |
| Celgene Corporation | $71.89 | 2023-2025 | Opdualag, Reblozyl, Zeposia |
| Astrazeneca Pharmaceuticals LP | $61.18 | 2025 | Imfinzi, Lynparza |
| Lilly USA, LLC | $60.21 | 2023 | Emgality, Amyvid |
| Genzyme Corporation | $58.02 | 2025 | |
| Tersera Therapeutics LLC | $56.57 | 2025 | Zoladex |
| Regeneron Healthcare Solutions, INC. | $56.27 | 2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $43.25 | 2025 | |
| Astellas Pharma US INC | $37.34 | 2025 | Xtandi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33.30 | 2023-2025 | |
| Pfizer INC. | $33.25 | 2025 | |
| Boston Scientific Corporation | $24.55 | 2025 | Farapulse |
| Eisai INC. | $24.48 | 2025 | |
| Lundbeck LLC | $24.40 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $22.65 | 2023 | Austedo Xr |
| Geron Corporation | $21.72 | 2025 | Rytelo |
| Mdd US Operations, LLC | $18.42 | 2023 | Gocovri |
| Takeda Pharmaceuticals U.S.A., INC. | $17.56 | 2025 | Fruzaqla |
| Genentech USA, INC. | $16.47 | 2025 | Polivy |
| Bayer Healthcare Pharmaceuticals INC. | $16.26 | 2025 | |
| Biogen, INC. | $16.24 | 2023 | Tysabri, Vumerity |
| Caris Mpi, INC. | $16.00 | 2025 | Mi Cancer Seek |
| Ipsen Biopharmaceuticals, INC | $14.92 | 2025 | Onivyde |
| Kyowa Kirin, INC. | $14.57 | 2025 | |
| Agios Pharmaceuticals, INC. | $14.39 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Bolanos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.